Drug
Balstilimab clinical trials
Also written AGEN2034.
- studies test it
- 41
- open now
- 18
- in phase 3
- 3
- first study started
- 2017
Keep track of what changes. Save the balstilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AGEN2034
- 36
Studies by the year they started
39 studies that test it; most in 2025 (9); 2 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 13
- Phase 2
- 29
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 32
Agenus Inc. (7) · City of Hope Medical Center (4) · Memorial Sloan Kettering Cancer Center (3) · Immune Oncology Research Institute (2) · National Cancer Institute (NCI) (2) · Northwestern University (1) · University of Colorado, Denver (1) · Nicholas DeVito, MD (1)
Often tested with
Tested in the same studies.
Botensilimab (27) · Zalifrelimab (6) · Doxorubicin (2) · Bevacizumab (2) · Allogeneic Invariant Natural Killer T-cells agenT-797 (2) · Paclitaxel (2) · Vorbipiprant (2) · Gemcitabine (2)
Studies
Open first, then newest update. How each study uses balstilimab is read from its arms, and is right about nine times in ten.
Testing it · 41
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07516366Written as Balstilimab
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3RecruitingPhase 2City of Hope Medical CenterNCT07595874Written as Balstilimab
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07551596Written as Balstilimab
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07227636Written as Balstilimab
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Balstilimab
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingPhase 2Benjamin SpielerNCT06843551Written as Balstilimab
- RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT07735624Written as Balstilimab
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingPhase 2Darren Sigal, MDNCT07550088Written as Balstilimab (BAL)
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06411691Written as Balstilimab
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryRecruitingPhase 2City of Hope Medical CenterNCT06780787Written as Balstilimab
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as Balstilimab
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingEarly Phase 1Northwell HealthNCT07193862Written as Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06843434Written as Balstilimab
- Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)RecruitingPhase 2Immune Oncology Research InstituteNCT05891821Written as Balstilimab
- Botensilimab, Balstilimab, and SBRT in Colorectal CancerRecruitingEarly Phase 1Massachusetts General HospitalNCT07128355Written as Balstilimab
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGRecruitingPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT04943848Written as Balstilimab
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingPhase 1University of Southern CaliforniaNCT06336902Written as Balstilimab
- A Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabRecruitingPhase 1/2ImmunoGenesisNCT06782555Written as Balstilimab
- Combination Immunotherapy in Colorectal CancerCompletedPhase 2Weill Medical College of Cornell UniversityNCT05571293Written as Balstilimab
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Northwestern UniversityNCT05864534Written as Balstilimab
See all 41 studies that test balstilimab →
Given in every arm · 10 — balstilimab is usual care beside what is tested
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06300463Written as Balstilimab
- A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.Not yet recruitingPhase 2Nelum CorpNCT07578337Written as Balstililmab
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsRecruitingPhase 2/3The Netherlands Cancer InstituteNCT06279130Written as balstilimab
- Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic CancerRecruitingPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06782932Written as Balstilimab
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedPhase 2Agenus Inc.NCT05529316Written as Balstilimab
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerTerminatedPhase 2Agenus Inc.NCT03894215Written as AGEN2034
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedPhase 1Agenus Inc.NCT05377528Written as Balstilimab
- Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal CancerWithdrawnPhase 2City of Hope Medical CenterNCT06575725Written as Balstilimab
- A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma PatientsWithdrawnPhase 2Targovax OyNCT05561491Written as Balstilimab
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaWithdrawnPhase 2Agenus Inc.NCT04607200Written as AGEN2034
Codes
What other systems call balstilimab · ClinicalTrials.gg INT001783
- MeSH (NLM) C000720935balstilimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1Q2QT5M7EOBALSTILIMABConfirmed FDA, NLM
- NCI Thesaurus C136465BalstilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720935 | balstilimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1Q2QT5M7EO | BALSTILIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C136465 | Balstilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.